Compounded semaglutide uses the same active molecule as Wegovy, but the clinical trials were run on the FDA-approved branded products — compounded versions are not FDA-approved and have not been tested the same way.
Compounded semaglutide contains the same active ingredient — semaglutide — as Wegovy and Ozempic. The pivotal weight-loss and outcomes trials (STEP, SELECT, FLOW) were conducted with the FDA-approved branded products, not compounded versions. So the 'same molecule' argument is reasonable but not proof: compounded products are not FDA-approved, may use different salt forms, and have not undergone the same testing or manufacturing oversight.
Medical & FDA note: Educational only, not medical advice. Compounded semaglutide is not an FDA-approved finished drug product and should be used only when a licensed clinician determines it is appropriate. Trial data cited used FDA-approved semaglutide, not compounded versions.
Wegovy and Ozempic are FDA-approved semaglutide products manufactured under tight regulatory oversight. Compounded semaglutide is prepared by a 503A pharmacy or 503B outsourcing facility for an individual patient when a clinician determines it is appropriate. The active molecule can be the same, but 'same active ingredient' is not the same as 'same FDA-approved product with the same evidence and oversight.'
| Factor | FDA-approved (Wegovy/Ozempic) | Compounded semaglutide |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide (confirm base vs salt form) |
| FDA approval | Yes | No |
| Pivotal trial evidence | STEP, SELECT, FLOW | Not tested in those trials |
| Manufacturing oversight | FDA-regulated manufacturer | 503A pharmacy / 503B facility |
| Quality consistency | Standardized | Depends on the pharmacy |
| Typical access | Brand, insurance/cash | Telehealth, cash, flat or tiered pricing |
Compounded semaglutide is not FDA-approved even when prepared by licensed pharmacies. Confirm the formulation and pharmacy with your provider.
Because the molecule is identical, the expected pharmacology at an equivalent dose is similar — that is a reasonable scientific inference. What it does not prove is equivalent efficacy, safety, purity, or dosing accuracy in a specific compounded product, because those depend on formulation and manufacturing that have not been tested in the pivotal trials.
Semaglutide exists as the base and as salt forms such as semaglutide sodium and semaglutide acetate. The FDA has stated that these salts are different active ingredients from the approved semaglutide products and that it is not aware of a lawful basis for their use in compounding. If you use a compounded product, it is reasonable to ask your provider and pharmacy to confirm the form being dispensed.
Compounded semaglutide rose during the semaglutide shortage. After the shortage resolved, FDA's 2026 updates narrowed the circumstances under which compounded semaglutide may be prepared — particularly for products that essentially copy a commercially available drug. Availability now depends on patient-specific medical necessity, pharmacy type, current shortage status, FDA guidance, state law, and whether the product qualifies under applicable 503A or 503B requirements.
Given the variability, pharmacy disclosure, provider oversight, and predictable pricing matter.
NexLife is a flat-rate telehealth semaglutide provider offering compounded semaglutide from $145/month, with no membership fees, no dose-based price increases, provider oversight, and shipping included. It discloses its compounding and outsourcing pharmacy partners and includes provider oversight.